N 2 (183) 2023. P. 51–55

CLINICAL BENEFIT OF USING CONTINUOUS MONITORING OF BLOOD GLUCOSE LEVELS IN PATIENTS WITH TYPE 2 DIABETES

V. I. Velychko, Yе. O. Tuliantseva, H. O. Danylchuk, O. O. Shapovalov

1Odesa National Medical University, Odesa, Ukraine

2Municipal Non-Commercial Enterprise “Children’s Advisory and Diagnostic Center named after Academician B. Ya. Reznik” of the Odesa City Council, Odesa, Ukraine

DOI 10.32782/2226-2008-2023-2-9

Type 2 diabetes has become a pandemic, the prevalence of which is increasing every year. Morbidity not only leads to damage, dysfunction and failure of various organs with the development of complications and early disability, worsens the quality of life of patients, but also burdens the health care system. Traditional methods of diabetes control are self-monitoring with a glucometer and determining the level of glycated hemoglobin. An evolution in blood glucose monitoring was the introduction of continuous glucose monitoring, which allows patients to detect episodes of hyper- and hypoglycemia during the day, the time in the glycemic range, and also notify the patient in case of deviation of indicators. The purpose of our study was to investigate the effectiveness and benefit of using a continuous blood glucose monitoring device in patients with type 2 diabetes. The study involved 18 patients with type 2 diabetes who were fitted with a device for continuous blood glucose monitoring for 14 days. Use of a continuous blood glucose monitoring system is undoubtedly useful and allows patients with diabetes to optimize diet and exercise and make informed therapeutic decisions. Therefore, it is important to carry out further research in this area, in order to prevent problems and risks associated with the control and treatment of diabetes, and to improve the quality of life of patients.

Key words: diabetes, continuous blood glucose monitoring, glycated hemoglobin, nocturnal hypoglycemia.

REFERENCES

  1. International Diabetes Federation. IDF Diabetes Atlas, 10th ed, issue 2021. [Electronic resource]. [Cited 01 May 2023] Available at: http://www.diabetesatlas.org.
  2. World Health Organization (WHO). 2022. [Cited 01 May 2023] Available at: https://www.who.int/news-room/fact-sheets/detail/diabetes.
  3. Atlas: Diabetes in Ukraine [Internet]. [Cited 2023 May 01]. Available: https://diabetesatlas.com.ua/ua.
  4. Zherdeva NN. The state of cognitive functions in patients with adult onset type 2 diabetes mellitus depending on sex, age and level of education. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY. 2021;13(5):324–328. (In Ukrainian). https://doi.org/10.22141/2224-0721.13.5.2017.110021.
  5. Piché ME, Tchernof A, Després JP. Obesity Phenotypes, Diabetes, and Cardiovascular Diseases. Circ Res. 2020;126(11):1477-1500. doi: 10.1161/CIRCRESAHA.120.316101.
  6. Biessels GJ, Whitmer RA. Cognitive dysfunction in diabetes: how to implement emerging guidelines. Diabetologia. 2020;63(1):3–9. https://doi.org/10.1007/s00125-019-04977-9.
  7. Mohammadi S, Karim NA, Talib RA, Amani R. Knowledge, attitude and practices on diabetes among Type 2 diabetic patients in Iran: A cross-sectional study. Science. 2015;3(4):520-4.
  8. Chehregosha H, Khamseh ME, Malek M, Hosseinpanah F, Ismail-Beigi F. A View Beyond HbA1c: Role of Continuous Glucose Monitoring. Diabetes Ther. 2019;10(3):853-863. doi: 10.1007/s13300-019-0619-1.
  9. Edelman SV, Argento NB, Pettus J, Hirsch IB. Clinical Implications of Real-time and Intermittently Scanned Continuous Glucose Monitoring. Diabetes Care. 2018;41(11):2265-2274. doi: 10.2337/dc18-1150.
  10. Sherwani SI, Khan HA, Ekhzaimy A, Masood A, Sakharkar MK. Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients. Biomark Insights. 2016;11:95-104. doi: 10.4137/BMI.S38440
  11. Kovatchev B, Cobelli C. Glucose Variability: Timing, Risk Analysis, and Relationship to Hypoglycemia in Diabetes. Diabetes Care. 2016;39(4):502-10. doi: 10.2337/dc15-2035. PMID: 27208366; PMCID: PMC4806774.
  12. Hirsch IB. Introduction: History of Glucose Monitoring. 2018 Aug. In: Role of Continuous Glucose Monitoring in Diabetes Treatment. Arlington (VA): American Diabetes Association; 2018 Aug. PMID: 34251770.
  13. Battelino T, Danne T, Bergenstal RM, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care. 2019;42(8):1593-1603. doi: https://doi.org/10.2337/dci19-0028.
  14. Beck RW, Bergenstal RM, Riddlesworth TD, et al. Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials. Diabetes Care. 2019;42(3):400-405. doi: https://doi.org/10.2337/dc18-1444.
  15. Mayeda L, Katz R, Ahmad I, et al. Glucose time in range and peripheral neuropathy in type 2 diabetes mellitus and chronic kidney disease. BMJ Open Diabetes Res Care. 2020;8(1):e000991. doi: https://doi.org/10.1136/bmjdrc-2019-000991.
View article PDF